skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: In the aging demographics trade, which of the three companies would you buy right now and which would you sell?

What are the valuation and growth projections for PLC and SIS?
Read Answer Asked by Max on July 27, 2020
Q: Hi,

I'm wondering if you might be able to provide me with some insight as to how you believe the Harvest Healthcare Leaders ETF appears to be able to sustain a yield of over 9%, when the vast majority of the investments it holds don't pay a dividend of anything close to that level of return and in fact in some cases pay no dividend at all?

I understand that they write covered calls on up to 33% of the portfolio but the difference between the return being paid by this ETF and the investments it holds seems too vast for those premiums to be able to make up all the difference. Am I perhaps mistaken in that belief or might this ETF being sustaining its current payout on "borrowed time"? I cannot afford any more investments like CPG or VET or any other examples of times I've reached for yield only to end up losing a massive percentage of my very hard earned money.

Thank you!
Read Answer Asked by Richard on July 27, 2020
Q: I don't currently have any exposure to health care/pharma companies and would like to start building a position in 2 or 3 companies. Can you please provide me with some names that you would recommend in this area, and the reasons why you think they are good investments.

thanks
Paula
Read Answer Asked by Paula on July 23, 2020
Q: Hello,
I couldn't find any questions on this ETF. PTH Invesco Healthcare ETF
Could I have your pros and cons list please?
Dave
Read Answer Asked by Dave on July 22, 2020
Q: Hi,
SVA & AZN are both in phase 3 of COVID-19 vaccine.
What are your thoughts about these companies?
Which one has the better financial ability to see the end of the vaccine development, approval and production of the vaccine (if their vaccine will prove itself successful).
Thanks,
Morris
Read Answer Asked by Morris on July 22, 2020
Q: This pharma. comp. recently had studies, showing positive results when linking a base drug to its hydrogen sulfide releasing molecule . so that the drug would be easier on the body when taken. Yet the stock went down from its high of $0.80 ( plus ) to the now price $ 0.42. Appreciate any comments you may have on this company and what the future might hold for the technique they are developing . Thanks
Read Answer Asked by Frank on July 21, 2020
Q: I am looking at US Healthcare (with the exception of WELL), how would you rank these companies in when considering balance sheet, management, growth potential, and MOAT?

Thanks,

Andrew
Read Answer Asked by Andrew on July 20, 2020
Q: Would you consider this company worthwhile for investing a initial small position?
Thank you
Read Answer Asked by Miroslaw on July 20, 2020
Q: Basically this is a follow-up to a healthcare question asked by Sean July 6. My only healthcare position is the steady eddie medical devices ETF IHI. I would like to diversity in this sector using another ETF or two that has similar potential returns to IHI. Candidates are:
ARKG Genomic Revolution
BTEC Healthcare Innovators
PTH Healthcare Momentum
Are any of these worth considering? Or is it best to purchase a few individual stocks? Pros and cons please. Thanks - James.
Read Answer Asked by James on July 17, 2020
Q: I have no medical training nor have I worked in the field of medical research.
I do, however, have some knowledge of that area and have followed advances for several decades.
What thoroughly stunned me was the discovery of CRISPR-Cas9 in the field of genetic engineering as well as our current ability to design molecules for use as therapeutics.
I have no doubt as to the success that will come in these areas. What stopped me from investing in them was the fact that so many people were working in these fields that choosing the wrong company seemed very possible. For example, who wants to buy the 3rd best cure for a disease threatening one of their own family. The many possible cures and therapies being investigated for Covid are examples of this.
It's rather like living in the early 20th century and becoming convinced that automobiles and airplanes might have a bright future, then going out and buying stock in Packard, Studebaker, Nash, Rambler, Hudson, etc. The list of failures goes on and on.
I finally bit on ABBV and CRISP just as we descended into Covid hell but not at the bottom. I chose ABBV for their expertise in therapeutics and CRSP for gene editing.
Fortunately I'm not asking you to comment on the technologies involved but rather on your impression of the abilities of both companies to manage their businesses. What are their cash reserves like? What's their current burn rate? When might they be next raising capital; that sort of thing.

In my earlier days I bought several positions in some truly impressive inventions. One actually resulted in several world records. Unfortunately they could neither manufacture nor sell the product. In fact some companies couldn't sell life preservers to a drowning man. The end is obvious. They went bankrupt.

Finally, you don't seem to include CRSP in your top picks in this area. I'm curious why. Don't like it, too many others to choose from or its European base?
Read Answer Asked by Larry on July 17, 2020
Q: Hi 5i Team - I have been reading an article in the Globe and Mail about the resurgence of investor interest in the biotech sector with a number of IPO's either recent or planned. Would you be able to recommend a few Canadian companies in this sector based on the following criteria: solid management, cash reserves for at least one year and preferably more, manageable debt, good growth prospects, any size capitalization but small to mid cap preferred, any risk level but not something that is purely speculative. These companies do not have to be on the forefront of Coronavirus research but could have innovative research into any health platforms. I am also interested in the U.S. side of this but will do this in another question. Thanks.
Rob
Read Answer Asked by Rob on July 17, 2020
Q: Hi,
Please explain why RIGL (US) is down today about 22% after it went up yesterday 100% (mid-day).
My exceptions for the stock were to go up & up after RIGL announce it's trial being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of COVID-19 pneumonia
Thanks,
Morris
Read Answer Asked by Morris on July 16, 2020
Q: The above company has come to my attention lately. They appear to have developed a drug NURTEC ODT for pain relief, migraine particularly. I believe the drone just received approval. They are also investors in Kleo Pharmaceuticals working on a Drug for the treatment of COVID-19. I believe Bill and Melinda Gates have just put in 5 million to the same company. I’m just wondering if you were aware of the company and if you are do you have any thoughts about it?

I found this interesting article in Yesterdays Globe and Mail
https://www.theglobeandmail.com/investing/markets/stocks/BHVN-N/pressreleases/88829/

Thanks John
Read Answer Asked by John on July 16, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!